qpi-1002
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02610283)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53AGONIST
TP53 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- qpi-1002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03510897 | Phase 3 | May 25, 2018 | Quark Pharmaceuticals |
| NCT02610283 | Phase 2 | Dec 1, 2015 | Quark Pharmaceuticals |
| NCT02610296 | Phase 3 | Dec 1, 2015 | Quark Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quark Pharmaceuticals | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1